Historique
Bulletin de Périodique
European Addiction Research , Vol.29, n°5 - October 2023
Paru le :
01/10/2023
Année
2023
Page(s) :
305-374
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- Concomitant drug use among opioid-dependent patients with and without attention deficit hyperactivity disorder: Does methylphenidate merit a trial? Tschudi L., Fischer S.K.M., Perlov E., Baumgartner M.R., Soyka M., Müller T.J., et al., p. 305-312.
- The role of adverse childhood experiences on people in opiate agonist treatment: The importance of feeling unloved. McDonagh D., de Vries J., Cominskey C., p. 313-322.
- Changes in opioid agonist treatment practice in Germany during the COVID-19 pandemic: What have physicians done, and what would they like to keep doing? Lehmann K., Kuhn S., Schulte B., Verthein U., p. 323-332.
- Incidence and determinants of COVID-19 in patients seeking treatment for substance use disorder: A patient-based linkage study. Lana-Lander I., Munoz-Galan R., Palacio-Vieira J., Majo-Roca X., Martinez-Carbonell E., Muga R., et al., p. 333-343.
- Association between cannabis use disorder and mental health disorders in the adolescent population: A cohort study. Munoz-Galan R., Lana-Lander I., Coronado M., Segura L., Colom J., p. 344-352.
- The impact of cue-elicited multisensory imagery on alcohol craving: A randomised controlled trial. Kiyak C., Deluca P., Norton S., Simonetti M.E., Preti E., p. 353-362.
- Legal approaches to new psychoactive substances: First empirical findings. van Amsterdam J., Burgess N., van den Brink W., p. 363-372.
- Concomitant drug use among opioid-dependent patients with and without attention deficit hyperactivity disorder: Does methylphenidate merit a trial? Tschudi L., Fischer S.K.M., Perlov E., Baumgartner M.R., Soyka M., Müller T.J., et al., p. 305-312.
- The role of adverse childhood experiences on people in opiate agonist treatment: The importance of feeling unloved. McDonagh D., de Vries J., Cominskey C., p. 313-322.
- Changes in opioid agonist treatment practice in Germany during the COVID-19 pandemic: What have physicians done, and what would they like to keep doing? Lehmann K., Kuhn S., Schulte B., Verthein U., p. 323-332.
- Incidence and determinants of COVID-19 in patients seeking treatment for substance use disorder: A patient-based linkage study. Lana-Lander I., Munoz-Galan R., Palacio-Vieira J., Majo-Roca X., Martinez-Carbonell E., Muga R., et al., p. 333-343.
- Association between cannabis use disorder and mental health disorders in the adolescent population: A cohort study. Munoz-Galan R., Lana-Lander I., Coronado M., Segura L., Colom J., p. 344-352.
- The impact of cue-elicited multisensory imagery on alcohol craving: A randomised controlled trial. Kiyak C., Deluca P., Norton S., Simonetti M.E., Preti E., p. 353-362.
- Legal approaches to new psychoactive substances: First empirical findings. van Amsterdam J., Burgess N., van den Brink W., p. 363-372.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection
R. MUNOZ-GALAN ;
I. LANA-LANDER ;
M. CORONADO ;
L. SEGURA ;
J. COLOM
|
2023
Dans European Addiction Research (Vol.29, n°5, October 2023) Article : Périodique
Dans European Addiction Research (Vol.29, n°5, October 2023) Article : Périodique
INTRODUCTION: According to the literature, early initiation to cannabis use and a dependent pattern of use are important risk factors for the development of mental health disorders. However, there are few cohort studies which look at the develop[...]
J. VAN AMSTERDAM ;
N. BURGESS ;
W. VAN DEN BRINK
|
2023
Dans European Addiction Research (Vol.29, n°5, October 2023) Article : Périodique
Dans European Addiction Research (Vol.29, n°5, October 2023) Article : Périodique
BACKGROUND: Generic drug legislation, i.e., simultaneously banning groups of drugs, has been introduced worldwide to counteract the trade and use of emerging "new psychoactive substances" (NPSs) more effectively.
SUMMARY: The potential and de f[...]